 Patients rolling over from Study WRI-GEV-007 will be screened to assure they fulfill the enrollment criteria. Screening must be performed within 30 days of initiating therapy, and imaging studies must be performed within 2 weeks of initiating therapy. Patients will be evaluated every 3 weeks during the study, including all safety assessments. Imaging studies will be performed every 2-3 months 8 - 12 weeks during study participation. Pharmacodynamic assessments, including evaluation of the immune response to SV-BR-1-GM will also be performed every 3 months. Patients who develop progressive disease may remain on the study if the Investigator feels they are deriving clinical benefit. For patients who come off the study, a final assessment will be carried out 2-4 weeks following the final treatment, including all safety assessments. Subjects will continue to be followed for survival analysis by phone call every 6 months. 